SCHEMBL453185

SCHEMBL453185

N#Cc1ccc(CO)cn1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 5/20 0.44
GRM2 Q14416 2/20 0.38
AR P10275 1/20 0.38
EGLN1 Q9GZT9 1/20 0.37
NAMPT P43490 1/20 0.36
BRD4 O60885 1/20 0.36
CYP11B1 P15538 2/20 0.36
CYP11B2 P19099 2/20 0.36
PARP14 Q460N5 1/20 0.36
FFAR1 O14842 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
KCNQ3 O43525 1/20 0.35
KCNQ2 O43526 1/20 0.35
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
EGLN2 Q96KS0 1/20 0.34
MALT1 Q9UDY8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5871891 0.84 GRM2 (0.42) CHEK1GRM2AREGLN1FFAR1
SCHEMBL3178017 0.81 CHEK1 (0.41) CHEK1GRM2AREGLN1CYP11B1
SCHEMBL26469110 0.80 CHEK1 (0.41) CHEK1GRM2AREGLN1NAMPT
SCHEMBL2643631 0.79 BRD4 (0.36) CHEK1GRM2AREGLN1NAMPT
SCHEMBL507109 0.79 AR (0.41) CHEK1GRM2AREGLN1NAMPT
SCHEMBL24146512 0.79 GAA (0.38) CHEK1GRM2ARNAMPTBRD4
SCHEMBL452013 0.79 BRD4 (0.36) CHEK1GRM2AREGLN1NAMPT
SCHEMBL1922759 0.79 GRM5 (0.36) CHEK1FFAR1FFAR4
SCHEMBL453184 0.79 BRD4 (0.39) CHEK1GRM2AREGLN1NAMPT
SCHEMBL31044550 0.79 GRM5 (0.36) CHEK1FFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570666-B2 Furoindazole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2026-03-10 US disclosed
WO-2025090792-A1 AMIDE PRODRUGS AND USES THEREOF AUTOBAHN THERAPEUTICS, INC. (US) 2025-05-01 WO disclosed
EP-4077334-B1 FUROINDAZOLE DERIVATIVES BAYER AG (DE) 2025-03-12 EP disclosed
CN-115135656-B Furanoindazole derivatives 拜耳公司 2024-06-14 CN disclosed
EP-3861001-B1 BORON CONTAINING PDE4 INHIBITORS PFIZER (US) 2023-12-13 EP disclosed
US-20230338344-A1 AMPK Activators and Methods of Use Thereof BIOVERATIV THERAPEUTICS INC. (US) 2023-10-26 US disclosed
EP-4221700-A1 AMPK ACTIVATORS AND METHODS OF USE THEREOF Bioverativ Therapeutics Inc. (US) 2023-08-09 EP disclosed
CN-112424182-B Cyclopentane compounds 迪哲(江苏)医药股份有限公司 2023-05-23 CN disclosed
US-20230148402-A1 Boron Containing PDE4 Inhibitors PFIZER INC. (US) 2023-05-11 US disclosed
US-20230112499-A1 FUROINDAZOLE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-0773955-A1 NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE BASF AKTIENGESELLSCHAFT (DE) 1997-05-21 EP disclosed
WO-1996024609-A1 THROMBIN INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 1996-08-15 WO disclosed
WO-1995035309-A1 NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE BASF AKTIENGESELLSCHAFT (DE) 1995-12-28 WO disclosed
EP-0212600-B1 NITROMETHYLENE DERIVATIVES NIHON BAYER AGROCHEM K.K. (JP) 1991-11-27 EP disclosed
US-4812454-A Nitromethylene derivatives and their use as insecticides NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1989-03-14 US disclosed
US-4772620-A MITICIDES, PARASITICIDES NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1988-09-20 US disclosed
EP-0212600-A2 Nitromethylene derivatives NIHON BAYER AGROCHEM K.K. (JP) 1987-03-04 EP disclosed
EP-0091464-B1 METHOD FOR THE PREPARATION OF CYANO-HETEROCYCLES SCHERING AKTIENGESELLSCHAFT (DE) 1986-04-16 EP disclosed
EP-0091464-A1 METHOD FOR THE PREPARATION OF CYANO-HETEROCYCLES. SCHERING AG (DE) 1983-10-19 EP disclosed
WO-1983001446-A1 METHOD FOR THE PREPARATION OF CYANO-HETEROCYCLES VORBRÜGGEN, Helmut 1983-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230338344-A1 AMPK Activators and Methods of Use Thereof PRKAG2, PRKAG3, PRKAG1 CHEK1 612/4885GRM2 2342/4885AR 1642/4885
US-20230112499-A1 FUROINDAZOLE DERIVATIVES PKD1, CYP11B1, PKD2 CHEK1 2769/4885GRM2 1657/4885AR 449/4885
US-12570666-B2 Furoindazole derivatives FURIN, CYP2F1, CYP3A7 CHEK1 2122/4885GRM2 3228/4885AR 3171/4885
US-20230148402-A1 Boron Containing PDE4 Inhibitors PDE4B, PDE4A, PDE3B CHEK1 4020/4885GRM2 4275/4885AR 1461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.